Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(CRL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
385.48(c) 385.77(c) 393.25(c) 396.32(c) 393.27(c) Last
396 138 208 364 218 500 237 757 206 751 Volume
+1.90% +0.08% +1.94% +0.78% -0.77% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3 523 M - -
Net income 2021 329 M - -
Net Debt 2021 1 860 M - -
P/E ratio 2021 61,1x
Yield 2021 -
Sales 2022 3 936 M - -
Net income 2022 481 M - -
Net Debt 2022 1 584 M - -
P/E ratio 2022 42,2x
Yield 2022 -
Capitalization 19 763 M 19 763 M -
EV / Sales 2021 6,14x
EV / Sales 2022 5,42x
Nbr of Employees 18 400
Free-Float 98,2%
More Financials
Company
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in... 
More about the company
Ratings of Charles River Laboratories International, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
07/20CHARLES RIVER LABORATORIES INTERNATI : Credit Suisse Adjusts Charles River Labor..
MT
07/13CHARLES RIVER LABORATORIES INTERNATI : Schedules Second-Quarter 2021 Earnings Re..
BU
07/02London Shares Gains as Miners, Builders Rise; Banks Fall
DJ
07/02BP : QinetiQ Names Successor as CFO Plans December Exit
MT
06/29CHARLES RIVER LABORATORIES INTERNATI : Completes $293 Million Acquisition Of Vig..
MT
06/29CHARLES RIVER LABORATORIES INTERNATI : Completes Acquisition of Vigene Bioscienc..
BU
06/29Charles River Laboratories International, Inc. completed the acquisition of V..
CI
06/25CHARLES RIVER LABORATORIES INTERNATI : CRL) added to Russell 1000 Value-Defensiv..
CI
06/25CHARLES RIVER LABORATORIES INTERNATI : CRL) added to Russell 1000 Growth-Defensi..
CI
06/25CHARLES RIVER LABORATORIES INTERNATI : CRL) added to Russell 1000 Defensive Inde..
CI
06/23COMBIGENE : GMP plasmids released - Ready to start GMP production of CG01
AQ
06/07CHARLES RIVER LABORATORIES INTERNATI : Signs Long-Term Solar Contract With Duke ..
MT
06/07CHARLES RIVER LABORATORIES INTERNATI : Announces Long-Term Solar Contract for No..
PU
06/07Charles River Laboratories Announces Long-Term Solar Contract for North Ameri..
CI
06/02INSIDER TRENDS : Insider at Charles River Labs International Tax Sale Continues ..
MT
More news
News in other languages on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
05/11STOCK MARKET PARIS : Trop vite, trop loin, trop fort ?
05/11EN DIRECT DES MARCHESá : Alstom, Crédit Agricole, Carbios, Pierre & Vacances, Lu..
04/01IRW-PRESS : Gold Terra Resource Corp.: Gold Terra meldet Einreichung eines techn..
02/26DGAP-NEWS : DLA Piper berät die Darlehensgeber bei der Refinanzierung des Warnow..
02/19LINEDATA SERVICES : Interview de Anvaraly Jiva, PDG de Linedata
More news
Analyst Recommendations on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
More recommendations
Stock Trading Strategies
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. - 2020
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Duration : Period :
Charles River Laboratories International, Inc. Technical Analysis Chart | CRL | US1598641074 | MarketScreener
Technical analysis trends CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 393,27 $
Average target price 366,14 $
Spread / Average Target -6,90%
EPS Revisions
Managers and Directors
James C. Foster Chairman, President & Chief Executive Officer
David Ross Smith Chief Financial Officer & Executive Vice President
Arthur C. Hubbs Chief Information Officer & Senior Vice President
Matthew L. Daniel Secretary & Chief Compliance Officer
Barbara j. Patterson Senior VP-Regulatory Affairs & Compliance
Sector and Competitors
1st jan.Capi. (M$)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.57.40%19 763
MODERNA, INC.221.50%140 065
LONZA GROUP AG20.60%55 634
IQVIA HOLDINGS INC.38.02%47 396
CELLTRION, INC.-26.46%31 265
SEAGEN INC.-18.34%25 955